76 2.3.3. La durée minimale de traitement, p.78 ,
82 3.4.1. L'arrêt du traitement en cas de cible, p.82 ,
le choix des critères 3. le choix de la méthode de mesure 4. le recueil des données 5. l'analyse des résultats : mise en évidence de points forts et points faibles 6. les plans d'actions d'amélioration et la réévaluation -« l'observation médicale ,
Non ou NA (non approprié)) pour chaque critère sont reportées dans un tableur EXCEL (Microsoft®) ,
Les AINS et les inhibiteurs de la cox-2: principaux effets indésirables, Forum Med Suisse, issue.6, pp.284-90, 2006. ,
Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs, New England Journal of Medicine, vol.340, issue.24, pp.1888-99, 1999. ,
DOI : 10.1056/NEJM199906173402407
Direct Medical Costs of Serious Gastrointestinal Ulcers among Users of NSAIDs, Drugs & Aging, vol.333, issue.6, pp.681-90, 2007. ,
DOI : 10.2165/00002512-200724080-00005
Analysis of the Costs of NSAID-Associated Gastropathy, PharmacoEconomics, vol.12, issue.1, pp.76-88, 1997. ,
DOI : 10.2165/00019053-199712010-00008
Profil des patients traités par AINS en Etude commandée par la HAS, 2007. ,
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage, The American Journal of Medicine, vol.86, issue.4, pp.449-58, 1989. ,
DOI : 10.1016/0002-9343(89)90344-6
The physiology of gastric acid secretion, N Engl J Med, vol.319, pp.1707-1722, 1988. ,
Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A propective observational cohort study, Arch Intern Med, issue.156, pp.1530-1566, 1996. ,
Recent considerations in nonsteroidal anti-inflammatory drug gastropathy, The American Journal of Medicine, vol.105, issue.1, pp.31-38, 1998. ,
DOI : 10.1016/S0002-9343(98)00072-2
A Nationwide Study of Mortality Associated with Hospital Admission Due to Severe Gastrointestinal Events and Those Associated with Nonsteroidal Antiinflammatory Drug Use, The American Journal of Gastroenterology, vol.114, issue.3, pp.100-1685, 2005. ,
DOI : 10.1111/j.1572-0241.2003.07517.x
Maladie ulcéreuse duodénale et gastrique non compliquée, Paris: Flammarion, pp.329-375, 2005. ,
Can Gastroduodenal Ulcers in NSAID Users Be Prevented?, Annals of Internal Medicine, vol.119, issue.4, pp.337-346, 1993. ,
DOI : 10.7326/0003-4819-119-4-199308150-00015
Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000. ,
DOI : 10.1136/bmj.320.7241.1036
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC27343
From experiment to experience: Side effects of nonsteroidal anti-inflammatory drugs, The American Journal of Medicine, vol.74, issue.5, pp.820-828, 1983. ,
DOI : 10.1016/0002-9343(83)91073-2
Comparaison of upper gastrointestinal toxicity of rofecoxib and naproxene in patients with rheumatoid arthritis. VIGOR Study Group, N Engl J Med, issue.21, pp.343-1520, 2000. ,
Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study, Rheumatology, vol.46, issue.2, pp.265-72, 2007. ,
DOI : 10.1093/rheumatology/kel223
Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: A case-control study, Scandinavian Journal of Gastroenterology, vol.23, issue.12, pp.1395-403, 2007. ,
DOI : 10.1046/j.1365-2036.1999.00488.x
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.43, issue.2, pp.370-377, 2000. ,
DOI : 10.1002/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D
Non steroidal anti-inflammatory drug gastropathy, Gastrointest Endosc Clin North Am, issue.6, pp.489-504, 1996. ,
Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs, Gastroenterology, vol.105, issue.4, pp.1078-88, 1993. ,
DOI : 10.1016/0016-5085(93)90952-9
Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs, Annals of Internal Medicine, vol.115, issue.10, pp.787-96, 1991. ,
DOI : 10.7326/0003-4819-115-10-787
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report, Gut, vol.56, issue.6, pp.772-81, 2007. ,
DOI : 10.1136/gut.2006.101634
Effects of Helicobacter pylori and Nonsteroidal Anti-Inflammatory Drugs on Peptic Ulcer Disease: A Systematic Review, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.130-172, 2006. ,
DOI : 10.1016/j.cgh.2005.10.006
The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption, The American Journal of Gastroenterology, vol.131, issue.11, pp.3189-96, 1999. ,
DOI : 10.1111/j.1572-0241.1999.01517.x
Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk of Upper Gastrointestinal Bleeding, New England Journal of Medicine, vol.343, issue.12, pp.834-843, 2000. ,
DOI : 10.1056/NEJM200009213431202
Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations, Gut, vol.55, issue.12, pp.1731-1739, 2006. ,
DOI : 10.1136/gut.2005.080754
Acute upper gastrointestinal bleeding inpatients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome, World J Gastroenterol, issue.11, pp.1365-1373, 2005. ,
DOI : 10.3748/wjg.v11.i9.1365
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250686
Comparaison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event trial (TARGET), Lancet, vol.354, pp.675-84, 2004. ,
Nonsteroidal Anti-inflammatory Drugs and the Risk of Hospitalization for Acute Renal Failure, Archives of Internal Medicine, vol.156, issue.21, pp.2433-2442, 1996. ,
DOI : 10.1001/archinte.1996.00440200041005
Consumption of nonsteroidal antiinflammatory drugs and the development of functional renal impairement in elderly subjects. Results of a case control study, Br J Clin Pharmacol, issue.44, pp.85-90, 1997. ,
Nonsteroidal anti-inflammatory drug nephrotoxicity. Should we be concerned ? Arch Intern Med, p.268, 1990. ,
DOI : 10.1001/archinte.1990.00390140024006
Renal Effects of COX-2-Selective Inhibitors, American Journal of Nephrology, vol.21, issue.1, pp.1-15, 2001. ,
DOI : 10.1159/000046212
Effect of rofecoxib, celecoxib, and naproxene on blood pressure and urinary sodium excretion in elderly volunteers, European congress of Rheumatology, 2001. ,
Medication use and the risk of Stevens-Johnson syndrome or toxidermal necrolysis, N Engl J Med, vol.60, pp.1600-1607, 1995. ,
Differencies in NSAID tolerability profile. Fact or fiction? Drug Saf, pp.183-95, 1994. ,
DOI : 10.2165/00002018-199410030-00001
Drugs in the etiology of agranulocytosis and aplastic anemia, Eur J Hematol, vol.60, pp.23-30, 1996. ,
HAS) Guide méthodologique: Elaboration de critères de qualité pour l'évaluation et l'amélioration des pratiques professionnelles, 2007. ,
HAS) Audit clinique ciblé appliqué à la "Prise en charge du patient sous AVK, 2006. ,
HAS) Prescription médicamenteuse chez le sujet âgé (3) -Lors d'une hospitalisation -évaluation du dossier, 2006. ,
Evaluation des pratiques professionnelles : un audit clinique sur la prescription et la surveillance des traitements par anti-inflammatoires non stéroïdiens en médecine générale, Thèse Méd Gén, pp.1-112, 2010. ,
Key elements for the summaries of product characteristics of the non-selective NSAIDs piroxicam, ketoprofen and ketorolac adopted by the CHMP, 2006. ,
Résumé des caractéristiques du produit (RCP): kétoprofène, 2009. ,
HAS) Bon usage du médicament: les inhibiteurs de la pompe à proton chez l'adulte, 2009. ,
A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines, Rheumatology, vol.44, issue.7, pp.44-921, 2005. ,
DOI : 10.1093/rheumatology/keh642
Non-steroidal anti-inflammatory drug prescriptions in hospital inpatients: are we assessing the risks?, Irish Journal of Medical Science, vol.26, issue.2, pp.357-60, 2010. ,
DOI : 10.1007/s11845-010-0496-0
Comment ??valuer le risque cardiovasculaire et r??nal ?? l?????chelon individuel?, La Presse M??dicale, vol.35, pp.35-40, 2006. ,
DOI : 10.1016/S0755-4982(06)74938-7
Risk Factors in the Development of Coronary Heart Disease. Six Year Follow-up Experience???The Framingham Study., Annals of Internal Medicine, vol.54, issue.5, pp.33-50, 1961. ,
DOI : 10.7326/0003-4819-54-5-1035_1
What is the impact of cardiovascular and renal complications on the benefit/risk ratio of the NSAIDs, Presse Med, pp.35-61, 2006. ,
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project, European Heart Journal, vol.24, issue.11, pp.987-1003, 2003. ,
DOI : 10.1016/S0195-668X(03)00114-3
Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population, American Journal of Kidney Diseases, vol.45, issue.3, pp.531-540, 2005. ,
DOI : 10.1053/j.ajkd.2004.12.005
How to watch over a patient treated with NSAID in relation to the cardiovascular and renal risk ,
Prescription des AINS chez les plus de 70 ans: évaluation de la pratique sur un échantillon de population de trois cabinets de médecine générale, Mémoire DES Méd Gén, pp.1-31, 2007. ,
Risk of Upper Gastrointestinal Complications Among Users of Traditional NSAIDs and COXIBs in the General Population, Gastroenterology, vol.132, issue.2, pp.498-506, 2007. ,
DOI : 10.1053/j.gastro.2006.12.007
Prescription des AINS en Bourgogne chez la personne âgée de plus de 70 ans, Rev Prat, vol.642, pp.248-52, 2004. ,
Enqu??te image: une ??tude observationnelle sur les prescriptionsd'anti-inflammatoires non st??ro??diens et de gastroprotecteurs. ??valuation des modes de prescription selon le profil des patients, Revue du Rhumatisme, vol.71, issue.71, pp.157-160, 2004. ,
DOI : 10.1016/S1169-8330(04)80020-6
Anti-inflammatoires non stéroïdiens et risques iatrogènes potentiels : analyse des données de l'assurance maladie, Rev Med Ass Maladie, vol.36, issue.2, pp.153-61, 2005. ,
Naturalistic survey on nonsteroidal antiinflammatory treatment in patients with musculoskeletal pain, Joint Bone Spine, vol.70, issue.3, pp.219-244, 2003. ,
DOI : 10.1016/S1297-319X(03)00047-2
Prevention of peptic ulcer and dyspeptic syndrome with omeprazol in patients receiving continuous nonsteroidal anti-inflammatory drug therapy. A nordic multicenre study ,
Audit of ketoprofen prescribing after orthopedic and general surgery, Canadian Journal of Anesthesia/Journal canadien d'anesth??sie, vol.275, issue.2, pp.109-122, 1999. ,
DOI : 10.1007/BF03012543
Concomitant Use of Gastroprotective Drugs among Elderly NSAID/COX-2 Selective Inhibitor Users, Clinical Drug Investigation, vol.17, issue.5, pp.687-95, 2008. ,
DOI : 10.2165/00044011-200828110-00002
Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs, Alimentary Pharmacology & Therapeutics, vol.22, issue.1, pp.31-40, 2007. ,
DOI : 10.1111/j.1365-2036.2007.03541.x
Connaissance de la pharmacologie des anti-inflammatoires non stéroïdiens par les médecins de la capitale d'Antananarivo, pp.100-102, 2008. ,
DOI : 10.1016/j.annfar.2007.10.039
Educational Program for Physicians to Reduce Use of Non-Steroidal Anti-Inflammatory Drugs Among Community-Dwelling Elderly Persons, Medical Care, vol.39, issue.5, pp.425-460, 2001. ,
DOI : 10.1097/00005650-200105000-00003
A group randomized trial to improve safe use of nonsteroidal anti-inflammatory drugs, Am J Manag Care, vol.11, issue.9, pp.537-580, 2005. ,
Guidelines for Prevention of NSAID-Related Ulcer Complications, The American Journal of Gastroenterology, vol.328, issue.3, pp.728-766, 2009. ,
DOI : 10.1038/ajg.2009.115
Connaissance par les médecins et les patients du risque de complications digestives des AINS, Presse Med, vol.32, issue.37, pp.4-48, 2003. ,
étage hebdomadaire -Orientation du patient : Discussion au colloque Médico-Chirurgical hebdomadaire Sortie Soins de suite à l'HRU SORTIE DU PATIENT : Examen clinique médical Evaluation quantitative de la douleur : EVA lombaire et radiculaire Prise de RDV de CS : Médecin Généraliste ,
en cas de prescription concomitante d'AINS et de traitement à risque, toutes les mesures de surveillance clinique et biologique sont appliquées ,
parmi âge >65 ans, AAP, AVK, antécédent d'ulcère ou hémorragie digestive) : AINS défini comme contre-indiqué ,